Lavish windfall gains from biotechnological unicorns
LOW RISK for entreprises
-
Fragmentation
-
Internationalization
-
Capital Intensity
-
Profitability
-
Fragmentation
-
Internationalization
-
Capital Intensity
-
Profitability
![](/content/dam/onemarketing/ehndbx/eulerhermes_com/en_gl/erd/icon/plus.png)
- Medicine demand bolstered by growing middle classes in Emerging Markets and aging population as a whole
- Resilience of drug spending irrespective of economic cycle, coupled with huge public support for improving people’s healthcare needs
- High level of R&D expenditure well covered by strong cash generation amid the pressing need for Covid-19 vaccines to reach herd immunity worldwide
- mRNA technology close to being a game-changer for the sector, especially in oncology treatments
- Venture capitalists and public investors’ appetite for investing in (listed) biotechnology firms
![](/content/dam/onemarketing/ehndbx/eulerhermes_com/en_gl/erd/icon/minus.png)
- Supply-chain disruptions due to states’ pressure to ‘reshore’ drug production within Western countries
- Lengthy procedures for new drug approvals on top of stiff price regulations
- Generic drug makers plagued with lower profit margins and higher debt gearing than patented drug ones
- Limited production capacities making it difficult to meet urgent delivery needs of all Covid-19 vaccines worldwide
- Bargaining power of India and China regarding vaccine production and delivery
Our information tracks the financial health of your customers and we update you so that you can trade with confidence.
If your customers become insolvent or fall into protracted default, you will be indemnified for the cost of goods and services you have delivered.
Key players
Country | Role | Sector risk |
---|---|---|
![]() |
#1 market by revenue |
A
Low risk |
![]() |
#2 market by revenue |
B
Medium risk |
![]() |
#3 market by revenue |
A
Low risk |
![]() |
#4 market by revenue |
A
Low risk |
![]() |
#5 market by revenue |
A
Low risk |
Let us help you today
Fill in the form below and our trade credit specialists will be in touch as soon as possible.
LATEST NEWS ABOUT PHARMACEUTICALS
-
Global trade: Battling out of demand and price shocks
The invasion of Ukraine and renewed Covid-19 outbreaks in China are hitting global trade with a double whammy in 2022: lower volumes and higher prices.
Russian dolls: unwrapping corporate (commodity) dependencies
A further +50% to 70% rise in non-energy commodity prices could actually wipe out all profits in six out of the nine sectors under analysis.
Economic Outlook: Energy, trade and financial shockwaves
The Russian invasion of Ukraine has brought back significant headwinds to the global economic recovery and raised wider geopolitical risks.